KORU Medical Beats Q1, Holds Guidance

KRMD just reported Q1 2026 results that came in ahead of expectations. Revenue hit $11.77 million, beating the $11.28 million estimate. Management held full-year guidance at $47.5–$50.0 million, in line with the consensus estimate of $48.5 million.

The stock entered the print in a constructive posture. Price closed at $4.08 on May 5, flat on the week but down about 6% over the past month. The earnings beat lands against that softness — and analysts who have covered the name are meaningfully above the current price. B. Riley Securities raised their target to $8.00 back in March (following a prior earnings release), Canaccord maintained at $6.00, and Lake Street is also at $8.00. That consensus price target of $6.80 implies roughly 67% upside from Wednesday's close. These moves are now about 54 days old, so carry them with appropriate weight — but the directional message from the Street remains bullish, with all active coverage sitting at Buy except one Neutral from Piper Sandler, which has a $4.00 target.

The EPS momentum picture supports the optimism in part. KORU's 90-day EPS momentum factor ranks in the 98th percentile of the universe — one of the highest readings available — though the 30-day momentum measure has dropped to the 12th percentile, suggesting recent estimate revisions have cooled. That divergence is worth noting: analysts were raising their models aggressively into year-end 2025, but the near-term revision momentum has since stalled. The Q1 beat may restart that cycle.

Positioning in the lending market is not the story here. Short interest is 1.6% of the free float, having crept up roughly 10% over the past month, but the absolute level remains low. Borrow is extraordinarily cheap at 0.73% — a 35% rise week-on-week, but still barely worth mentioning in context. Availability is ample. Options sentiment is modestly call-skewed: the put/call ratio of 0.25 runs slightly below its 20-day average of 0.28 and well below the 52-week high of 0.39 from earlier this year. None of these signals point to any meaningful short pressure or defensive positioning.

Institutional ownership tells a more interesting story. Horton Capital Management holds 23.5% of shares and reported a substantial increase — adding over 5 million shares — in their latest filing as of early April. That's a dominant single-holder position for a small-cap device company. The CEO, Linda Tharby, holds a 2.56% stake and added shares via an October 2025 award, though she also completed a modest tax-related sell in March 2026. The insider transactions in March were largely grant-related, with only small same-day sell-to-cover transactions by the COO and CFO alongside awards — standard equity compensation activity with no negative signal.

The two most recent prior earnings reactions give limited comfort to bulls: the April 2026 release (from March 12 results) produced a 5.1% one-day loss and a further 4.7% decline over the following five days. The next print, on April 29, added another 2.2% one-day drawdown. The pattern is consistent — good operating metrics have not reliably translated into positive price reactions on earnings days. Whether tonight's beat from Q1 2026 breaks that streak is the key variable to watch in tomorrow's session.